NEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) — Gelteq Limited (“Gelteq” or the “Company”), a global biotechnology company that specializes in the formulation, development, and manufacturing of ingestible gel technology, announced today that it has priced its initial public offering of 1,300,000 ordinary shares of the Company at a public offering price of US$4.00 per share. The shares have been approved for listing on the Nasdaq Capital Market (“Nasdaq”). Trading on Nasdaq is expected to begin on October 29, 2024 under the symbol “GELS.”
The gross proceeds from the offering, before deducting underwriting fees and other offering expenses payable by the Company, are expected to be US$5.2 million. The offering is expected to close on or about October 30, 2024, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for various purposes, including funding certain manufacturing, marketing and research and development activities.
The Benchmark Company, LLC is acting as the lead managing underwriter for the offering. The Company has granted the underwriter a 45-day option …
Full story available on Benzinga.com
NEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) — Gelteq Limited (“Gelteq” or the “Company”), a global biotechnology company that specializes in the formulation, development, and manufacturing of ingestible gel technology, announced today that it has priced its initial public offering of 1,300,000 ordinary shares of the Company at a public offering price of US$4.00 per share. The shares have been approved for listing on the Nasdaq Capital Market (“Nasdaq”). Trading on Nasdaq is expected to begin on October 29, 2024 under the symbol “GELS.”
The gross proceeds from the offering, before deducting underwriting fees and other offering expenses payable by the Company, are expected to be US$5.2 million. The offering is expected to close on or about October 30, 2024, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for various purposes, including funding certain manufacturing, marketing and research and development activities.
The Benchmark Company, LLC is acting as the lead managing underwriter for the offering. The Company has granted the underwriter a 45-day option …
Full story available on Benzinga.com
NEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) — Gelteq Limited (“Gelteq” or the “Company”), a global biotechnology company that specializes in the formulation, development, and manufacturing of ingestible gel technology, announced today that it has priced its initial public offering of 1,300,000 ordinary shares of the Company at a public offering price of US$4.00 per share. The shares have been approved for listing on the Nasdaq Capital Market (“Nasdaq”). Trading on Nasdaq is expected to begin on October 29, 2024 under the symbol “GELS.”
The gross proceeds from the offering, before deducting underwriting fees and other offering expenses payable by the Company, are expected to be US$5.2 million. The offering is expected to close on or about October 30, 2024, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for various purposes, including funding certain manufacturing, marketing and research and development activities.
The Benchmark Company, LLC is acting as the lead managing underwriter for the offering. The Company has granted the underwriter a 45-day option …Full story available on Benzinga.com Read MoreNews, IPOs, Press Releases IPOs
